Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
126,754,706
-
Share change
-
+1,609,804
-
Total reported value
-
$3,691,746,017
-
Put/Call ratio
-
39%
-
Price per share
-
$29.13
-
Number of holders
-
215
-
Value change
-
+$83,332,107
-
Number of buys
-
110
-
Number of sells
-
80
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q3 2024
As of 30 Sep 2024,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
215 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
126,754,706 shares.
The largest 10 holders included
BlackRock, Inc., BAILLIE GIFFORD & CO, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Capital Research Global Investors, FMR LLC, Temasek Holdings (Private) Ltd, Crestline Management, LP, STATE STREET CORP, and UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC.
This page lists
215
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.